Generics Global Industry Almanac 2019-2028
Summary
Global Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume , and forecast to 2028). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
- A generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and branded generics are included in our market scope. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included. Âé¶¹Ô´´ value is evaluated at ex-factory prices. Âé¶¹Ô´´ volume refers to the proportion of the total ethical pharmaceutical market in a country or region that is made up of generic drugs. Thus, it is a measure of the market share held by generics, rather than a direct measure of the total market volume. Regional volumes are calculated as averages of countries that comprise the region where volume data exists.
- All market data and forecasts are adjusted for inflation and all currency conversions used in the creation of this report have been calculated using yearly annual average exchange rates.
- The global generics market recorded revenues of $394.6 billion in 2023, representing a compound annual growth rate (CAGR) of 7.8% between 2018 and 2023.
- Âé¶¹Ô´´ consumption volume increased with a CAGR of 1.4% between 2018 and 2023, to reach a total of 51.4% of total pharma volume in 2023.
- According to GlobalData, in 2023, Asia-Pacific accounting for a share of 47.7%, was the largest generics market globally. The dominance of the region is driven by its large-scale manufacturing capabilities, cost-competitive production, and robust supply chain infrastructure.
Scope
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the global generics market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the global generics market
- Leading company profiles reveal details of key generics market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the global generics market with five year forecasts by both value and volume
Reasons to Buy
- What was the size of the global generics market by value in 2023?
- What will be the size of the global generics market in 2028?
- What factors are affecting the strength of competition in the global generics market?
- How has the market performed over the last five years?
- How large is the global generics market in relation to its regional counterparts?
Table of Contents
1 EXECUTIVE SUMMARY
1.1. Âé¶¹Ô´´ value
1.2. Âé¶¹Ô´´ value forecast
1.3. Âé¶¹Ô´´ volume
1.4. Âé¶¹Ô´´ volume forecast
1.5. Geography segmentation
1.6. Competitive landscape
2 Introduction
2.1. What is this report about?
2.2. Who is the target reader?
2.3. How to use this report
2.4. Definitions
3 Global Generics
3.1. Âé¶¹Ô´´ Overview
3.2. Âé¶¹Ô´´ Data
3.3. Âé¶¹Ô´´ Segmentation
3.4. Âé¶¹Ô´´ outlook
3.5. Five forces analysis
4 Macroeconomic Indicators
4.1. Country data
5 Generics in Asia-Pacific
5.1. Âé¶¹Ô´´ Overview
5.2. Âé¶¹Ô´´ Data
5.3. Âé¶¹Ô´´ Segmentation
5.4. Âé¶¹Ô´´ outlook
5.5. Five forces analysis
6 Generics in Europe
6.1. Âé¶¹Ô´´ Overview
6.2. Âé¶¹Ô´´ Data
6.3. Âé¶¹Ô´´ Segmentation
6.4. Âé¶¹Ô´´ outlook
6.5. Five forces analysis
7 Macroeconomic Indicators
7.1. Country data
8 Generics in France
8.1. Âé¶¹Ô´´ Overview
8.2. Âé¶¹Ô´´ Data
8.3. Âé¶¹Ô´´ Segmentation
8.4. Âé¶¹Ô´´ outlook
8.5. Five forces analysis
9 Macroeconomic Indicators
9.1. Country data
10 Generics in Germany
10.1. Âé¶¹Ô´´ Overview
10.2. Âé¶¹Ô´´ Data
10.3. Âé¶¹Ô´´ Segmentation
10.4. Âé¶¹Ô´´ outlook
10.5. Five forces analysis
11 Macroeconomic Indicators
11.1. Country data
12 Generics in Australia
12.1. Âé¶¹Ô´´ Overview
12.2. Âé¶¹Ô´´ Data
12.3. Âé¶¹Ô´´ Segmentation
12.4. Âé¶¹Ô´´ outlook
12.5. Five forces analysis
13 Macroeconomic Indicators
13.1. Country data
14 Generics in Brazil
14.1. Âé¶¹Ô´´ Overview
14.2. Âé¶¹Ô´´ Data
14.3. Âé¶¹Ô´´ Segmentation
14.4. Âé¶¹Ô´´ outlook
14.5. Five forces analysis
15 Macroeconomic Indicators
15.1. Country data
16 Generics in Canada
16.1. Âé¶¹Ô´´ Overview
16.2. Âé¶¹Ô´´ Data
16.3. Âé¶¹Ô´´ Segmentation
16.4. Âé¶¹Ô´´ outlook
16.5. Five forces analysis
17 Macroeconomic Indicators
17.1. Country data
18 Generics in China
18.1. Âé¶¹Ô´´ Overview
18.2. Âé¶¹Ô´´ Data
18.3. Âé¶¹Ô´´ Segmentation
18.4. Âé¶¹Ô´´ outlook
18.5. Five forces analysis
19 Macroeconomic Indicators
19.1. Country data
20 Generics in India
20.1. Âé¶¹Ô´´ Overview
20.2. Âé¶¹Ô´´ Data
20.3. Âé¶¹Ô´´ Segmentation
20.4. Âé¶¹Ô´´ outlook
20.5. Five forces analysis
21 Macroeconomic Indicators
21.1. Country data
22 Generics in Indonesia
22.1. Âé¶¹Ô´´ Overview
22.2. Âé¶¹Ô´´ Data
22.3. Âé¶¹Ô´´ Segmentation
22.4. Âé¶¹Ô´´ outlook
22.5. Five forces analysis
23 Macroeconomic Indicators
23.1. Country data
24 Generics in Italy
24.1. Âé¶¹Ô´´ Overview
24.2. Âé¶¹Ô´´ Data
24.3. Âé¶¹Ô´´ Segmentation
24.4. Âé¶¹Ô´´ outlook
24.5. Five forces analysis
25 Macroeconomic Indicators
25.1. Country data
26 Generics in Japan
26.1. Âé¶¹Ô´´ Overview
26.2. Âé¶¹Ô´´ Data
26.3. Âé¶¹Ô´´ Segmentation
26.4. Âé¶¹Ô´´ outlook
26.5. Five forces analysis
27 Macroeconomic Indicators
27.1. Country data
28 Generics in Mexico
28.1. Âé¶¹Ô´´ Overview
28.2. Âé¶¹Ô´´ Data
28.3. Âé¶¹Ô´´ Segmentation
28.4. Âé¶¹Ô´´ outlook
28.5. Five forces analysis
29 Macroeconomic Indicators
29.1. Country data
30 Generics in The Netherlands
30.1. Âé¶¹Ô´´ Overview
30.2. Âé¶¹Ô´´ Data
30.3. Âé¶¹Ô´´ Segmentation
30.4. Âé¶¹Ô´´ outlook
30.5. Five forces analysis
31 Macroeconomic Indicators
31.1. Country data
32 Generics in North America
32.1. Âé¶¹Ô´´ Overview
32.2. Âé¶¹Ô´´ Data
32.3. Âé¶¹Ô´´ Segmentation
32.4. Âé¶¹Ô´´ outlook
32.5. Five forces analysis
33 Generics in Russia
33.1. Âé¶¹Ô´´ Overview
33.2. Âé¶¹Ô´´ Data
33.3. Âé¶¹Ô´´ Segmentation
33.4. Âé¶¹Ô´´ outlook
33.5. Five forces analysis
34 Macroeconomic Indicators
34.1. Country data
35 Generics in Scandinavia
35.1. Âé¶¹Ô´´ Overview
35.2. Âé¶¹Ô´´ Data
35.3. Âé¶¹Ô´´ Segmentation
35.4. Âé¶¹Ô´´ outlook
35.5. Five forces analysis
36 Generics in Singapore
36.1. Âé¶¹Ô´´ Overview
36.2. Âé¶¹Ô´´ Data
36.3. Âé¶¹Ô´´ Segmentation
36.4. Âé¶¹Ô´´ outlook
36.5. Five forces analysis
37 Macroeconomic Indicators
37.1. Country data
38 Generics in South Africa
38.1. Âé¶¹Ô´´ Overview
38.2. Âé¶¹Ô´´ Data
38.3. Âé¶¹Ô´´ Segmentation
38.4. Âé¶¹Ô´´ outlook
38.5. Five forces analysis
39 Macroeconomic Indicators
39.1. Country data
40 Generics in South Korea
40.1. Âé¶¹Ô´´ Overview
40.2. Âé¶¹Ô´´ Data
40.3. Âé¶¹Ô´´ Segmentation
40.4. Âé¶¹Ô´´ outlook
40.5. Five forces analysis
41 Macroeconomic Indicators
41.1. Country data
42 Generics in Spain
42.1. Âé¶¹Ô´´ Overview
42.2. Âé¶¹Ô´´ Data
42.3. Âé¶¹Ô´´ Segmentation
42.4. Âé¶¹Ô´´ outlook
42.5. Five forces analysis
43 Macroeconomic Indicators
43.1. Country data
44 Generics in Turkey
44.1. Âé¶¹Ô´´ Overview
44.2. Âé¶¹Ô´´ Data
44.3. Âé¶¹Ô´´ Segmentation
44.4. Âé¶¹Ô´´ outlook
44.5. Five forces analysis
45 Macroeconomic Indicators
45.1. Country data
46 Generics in The United Kingdom
46.1. Âé¶¹Ô´´ Overview
46.2. Âé¶¹Ô´´ Data
46.3. Âé¶¹Ô´´ Segmentation
46.4. Âé¶¹Ô´´ outlook
46.5. Five forces analysis
47 Macroeconomic Indicators
47.1. Country data
48 Generics in The United States
48.1. Âé¶¹Ô´´ Overview
48.2. Âé¶¹Ô´´ Data
48.3. Âé¶¹Ô´´ Segmentation
48.4. Âé¶¹Ô´´ outlook
48.5. Five forces analysis
49 Macroeconomic Indicators
49.1. Country data
50 Company Profiles
50.1. Teva Pharmaceutical Industries Ltd
50.2. Viatris Inc
50.3. Sun Pharmaceutical Industries Ltd
50.4. Novartis AG
50.5. Sandoz Group AG
50.6. Hikma Pharmaceuticals Plc
50.7. Sanofi
50.8. Les Laboratoires Servier SAS
50.9. Stada Arzneimittel AG
50.10. Bayer AG
50.11. Lupin Ltd
50.12. Aspen Pharmacare Holdings Ltd
50.13. EMS SA
50.14. Eurofarma Laboratorios SA
50.15. Ache Laboratorios Farmaceuticos SA
50.16. Apotex Inc
50.17. Teva Canada Ltd
50.18. Sandoz Canada Inc
50.19. CSPC Pharmaceutical Group Ltd
50.20. Sino Biopharmaceutical Ltd
50.21. Hansoh Pharmaceutical Group Co Ltd
50.22. Dr. Reddy's Laboratories Ltd
50.23. Cipla Ltd
50.24. Aurobindo Pharma Ltd
50.25. PT Kalbe Farma Tbk
50.26. PT Indofarma Tbk
50.27. PT Sanbe Farma
50.28. PT Soho Global Health Tbk
50.29. Friulchem SpA
50.30. DOC Generici SRL
50.31. Recordati SpA
50.32. Daiichi Sankyo Co Ltd
50.33. Towa Pharmaceutical Co Ltd
50.34. Sawai Group Holdings Co Ltd
50.35. Toho Holdings Co Ltd
50.36. Laboratorios Silanes SA de CV
50.37. Pfizer Inc
50.38. Biocad
50.39. R-Pharm
50.40. Pharmstandard
50.41. AstraZeneca Plc
50.42. Bluefish Pharmaceuticals AB
50.43. Navamedic ASA
50.44. Novartis International AG
50.45. Beacons Pharmaceuticals Pte Ltd
50.46. Abbott Laboratories SA
50.47. Adcock Ingram Holdings Ltd
50.48. Dongkook Pharmaceutical Co Ltd
50.49. JW Holdings Corp
50.50. Hanmi Pharmaceuticals Co Ltd
50.51. Dong Wha Pharma Co Ltd
50.52. Esteve Pharmaceuticals SA
50.53. Abdi Ibrahim Ilac Sanayi ve Ticaret AS
50.54. Deva Holding AS
50.55. Sandoz Inc
51 Appendix
51.1. Methodology
51.2. About Âé¶¹Ô´´Line
List of Tables
List of Tables
Table 1: Global generics market value: $ million, 2018-23
Table 2: Global generics market volume: % of total pharma volume, 2018-23
Table 3: Global generics market geography segmentation: $ million, 2023
Table 4: Global generics market value forecast: $ million, 2023-28
Table 5: Global generics market volume forecast: % of total pharma volume, 2023-28
Table 6: Global Size of Population (million), 2019-23
Table 7: Global real GDP (Constant 2010 Prices, $ billion), 2019-23
Table 8: Global GDP (Current Prices, $ Billion), 2019-23
Table 9: Global Inflation, 2019-23
Table 10: Global Consumer Price Index (Absolute), 2019-23
Table 11: Global exchange rate, 2018-23
Table 12: Asia-Pacific generics market value: $ million, 2018-23
Table 13: Asia-Pacific generics market volume: % of total pharma volume, 2018-23
Table 14: Asia-Pacific generics market geography segmentation: $ million, 2023
Table 15: Asia-Pacific generics market value forecast: $ million, 2023-28
Table 16: Asia-Pacific generics market volume forecast: % of total pharma volume, 2023-28
Table 17: Europe generics market value: $ million, 2018-23
Table 18: Europe generics market volume: % of total pharma volume, 2018-23
Table 19: Europe generics market geography segmentation: $ million, 2023
Table 20: Europe generics market value forecast: $ million, 2023-28
Table 21: Europe generics market volume forecast: % of total pharma volume, 2023-28
Table 22: Europe Size of Population (million), 2019-23
Table 23: Europe real GDP (Constant 2010 Prices, $ billion), 2019-23
Table 24: Europe GDP (Current Prices, $ Billion), 2019-23
Table 25: Europe Inflation, 2019-23
Table 26: Europe Consumer Price Index (Absolute), 2019-23
Table 27: Europe exchange rate, 2018-23
Table 28: France generics market value: $ million, 2018-23
Table 29: France generics market volume: % of total pharma volume, 2018-23
Table 30: France generics market geography segmentation: $ million, 2023
Table 31: France generics market value forecast: $ million, 2023-28
Table 32: France generics market volume forecast: % of total pharma volume, 2023-28
Table 33: France Size of Population (million), 2019-23
Table 34: France real GDP (Constant 2010 Prices, $ billion), 2019-23
Table 35: France GDP (Current Prices, $ Billion), 2019-23
Table 36: France Inflation, 2019-23
Table 37: France Consumer Price Index (Absolute), 2019-23
Table 38: France exchange rate, 2018-23
Table 39: Germany generics market value: $ million, 2018-23
Table 40: Germany generics market volume: % of total pharma volume, 2018-23
Table 41: Germany generics market geography segmentation: $ million, 2023
Table 42: Germany generics market value forecast: $ million, 2023-28
Table 43: Germany generics market volume forecast: % of total pharma volume, 2023-28
Table 44: Germany Size of Population (million), 2019-23
Table 45: Germany real GDP (Constant 2010 Prices, $ billion), 2019-23
Table 46: Germany GDP (Current Prices, $ Billion), 2019-23
Table 47: Germany Inflation, 2019-23
Table 48: Germany Consumer Price Index (Absolute), 2019-23
Table 49: Germany exchange rate, 2018-23
Table 50: Australia generics market value: $ million, 2018-23
Table 51: Australia generics market volume: % of total pharma volume, 2018-23
Table 52: Australia generics market geography segmentation: $ million, 2023
Table 53: Australia generics market value forecast: $ million, 2023-28
Table 54: Australia generics market volume forecast: % of total pharma volume, 2023-28
Table 55: Australia Size of Population (million), 2019-23
Table 56: Australia real GDP (Constant 2010 Prices, $ billion), 2019-23
Table 57: Australia GDP (Current Prices, $ Billion), 2019-23
Table 58: Australia Inflation, 2019-23
Table 59: Australia Consumer Price Index (Absolute), 2019-23
Table 60: Australia exchange rate, 2018-23
Table 61: Brazil generics market value: $ million, 2018-23
Table 62: Brazil generics market volume: % of total pharma volume, 2018-23
Table 63: Brazil generics market geography segmentation: $ million, 2023
Table 64: Brazil generics market value forecast: $ million, 2023-28
Table 65: Brazil generics market volume forecast: % of total pharma volume, 2023-28
Table 66: Brazil Size of Population (million), 2019-23
Table 67: Brazil real GDP (Constant 2010 Prices, $ billion), 2019-23
Table 68: Brazil GDP (Current Prices, $ Billion), 2019-23
Table 69: Brazil Inflation, 2019-23
Table 70: Brazil Consumer Price Index (Absolute), 2019-23
Table 71: Brazil exchange rate, 2018-23
Table 72: Canada generics market value: $ million, 2018-23
Table 73: Canada generics market volume: % of total pharma volume, 2018-23
Table 74: Canada generics market geography segmentation: $ million, 2023
Table 75: Canada generics market value forecast: $ million, 2023-28
Table 76: Canada generics market volume forecast: % of total pharma volume, 2023-28
Table 77: Canada Size of Population (million), 2019-23
Table 78: Canada real GDP (Constant 2010 Prices, $ billion), 2019-23
Table 79: Canada GDP (Current Prices, $ Billion), 2019-23
Table 80: Canada Inflation, 2019-23
Table 81: Canada Consumer Price Index (Absolute), 2019-23
Table 82: Canada exchange rate, 2018-23
Table 83: China generics market value: $ million, 2018-23
Table 84: China generics market volume: % of total pharma volume, 2018-23
Table 85: China generics market geography segmentation: $ million, 2023
Table 86: China generics market value forecast: $ million, 2023-28
Table 87: China generics market volume forecast: % of total pharma volume, 2023-28
Table 88: China Size of Population (million), 2019-23
Table 89: China real GDP (Constant 2010 Prices, $ billion), 2019-23
Table 90: China GDP (Current Prices, $ Billion), 2019-23
Table 91: China Inflation, 2019-23
Table 92: China Consumer Price Index (Absolute), 2019-23
Table 93: China exchange rate, 2018-23
Table 94: India generics market value: $ million, 2018-23
Table 95: India generics market volume: % of total pharma volume, 2018-23
Table 96: India generics market geography segmentation: $ million, 2023
Table 97: India generics market value forecast: $ million, 2023-28
Table 98: India generics market volume forecast: % of total pharma volume, 2023-28
Table 99: India Size of Population (million), 2019-23
Table 100: India real GDP (Constant 2010 Prices, $ billion), 2019-23
Table 101: India GDP (Current Prices, $ Billion), 2019-23
Table 102: India Inflation, 2019-23
List of Figures
List of Figures
Figure 1: Global generics market value: $ million, 2018-23
Figure 2: Global generics market volume: % of total pharma volume, 2018-23
Figure 3: Global generics market geography segmentation: % share, by value, 2023
Figure 4: Global generics market value forecast: $ million, 2023-28
Figure 5: Global generics market volume forecast: % of total pharma volume, 2023-28
Figure 6: Forces driving competition in the global generics market, 2023
Figure 7: Drivers of buyer power in the global generics market, 2023
Figure 8: Drivers of supplier power in the global generics market, 2023
Figure 9: Factors influencing the likelihood of new entrants in the global generics market, 2023
Figure 10: Factors influencing the threat of substitutes in the global generics market, 2023
Figure 11: Drivers of degree of rivalry in the global generics market, 2023
Figure 12: Asia-Pacific generics market value: $ million, 2018-23
Figure 13: Asia-Pacific generics market volume: % of total pharma volume, 2018-23
Figure 14: Asia-Pacific generics market geography segmentation: % share, by value, 2023
Figure 15: Asia-Pacific generics market value forecast: $ million, 2023-28
Figure 16: Asia-Pacific generics market volume forecast: % of total pharma volume, 2023-28
Figure 17: Forces driving competition in the generics market in Asia-Pacific, 2023
Figure 18: Drivers of buyer power in the generics market in Asia-Pacific, 2023
Figure 19: Drivers of supplier power in the generics market in Asia-Pacific, 2023
Figure 20: Factors influencing the likelihood of new entrants in the generics market in Asia-Pacific, 2023
Figure 21: Factors influencing the threat of substitutes in the generics market in Asia-Pacific, 2023
Figure 22: Drivers of degree of rivalry in the generics market in Asia-Pacific, 2023
Figure 23: Europe generics market value: $ million, 2018-23
Figure 24: Europe generics market volume: % of total pharma volume, 2018-23
Figure 25: Europe generics market geography segmentation: % share, by value, 2023
Figure 26: Europe generics market value forecast: $ million, 2023-28
Figure 27: Europe generics market volume forecast: % of total pharma volume, 2023-28
Figure 28: Forces driving competition in the generics market in Europe, 2023
Figure 29: Drivers of buyer power in the generics market in Europe, 2023
Figure 30: Drivers of supplier power in the generics market in Europe, 2023
Figure 31: Factors influencing the likelihood of new entrants in the generics market in Europe, 2023
Figure 32: Factors influencing the threat of substitutes in the generics market in Europe, 2023
Figure 33: Drivers of degree of rivalry in the generics market in Europe, 2023
Figure 34: France generics market value: $ million, 2018-23
Figure 35: France generics market volume: % of total pharma volume, 2018-23
Figure 36: France generics market geography segmentation: % share, by value, 2023
Figure 37: France generics market value forecast: $ million, 2023-28
Figure 38: France generics market volume forecast: % of total pharma volume, 2023-28
Figure 39: Forces driving competition in the generics market in France, 2023
Figure 40: Drivers of buyer power in the generics market in France, 2023
Figure 41: Drivers of supplier power in the generics market in France, 2023
Figure 42: Factors influencing the likelihood of new entrants in the generics market in France, 2023
Figure 43: Factors influencing the threat of substitutes in the generics market in France, 2023
Figure 44: Drivers of degree of rivalry in the generics market in France, 2023
Figure 45: Germany generics market value: $ million, 2018-23
Figure 46: Germany generics market volume: % of total pharma volume, 2018-23
Figure 47: Germany generics market geography segmentation: % share, by value, 2023
Figure 48: Germany generics market value forecast: $ million, 2023-28
Figure 49: Germany generics market volume forecast: % of total pharma volume, 2023-28
Figure 50: Forces driving competition in the generics market in Germany, 2023
Figure 51: Drivers of buyer power in the generics market in Germany, 2023
Figure 52: Drivers of supplier power in the generics market in Germany, 2023
Figure 53: Factors influencing the likelihood of new entrants in the generics market in Germany, 2023
Figure 54: Factors influencing the threat of substitutes in the generics market in Germany, 2023
Figure 55: Drivers of degree of rivalry in the generics market in Germany, 2023
Figure 56: Australia generics market value: $ million, 2018-23
Figure 57: Australia generics market volume: % of total pharma volume, 2018-23
Figure 58: Australia generics market geography segmentation: % share, by value, 2023
Figure 59: Australia generics market value forecast: $ million, 2023-28
Figure 60: Australia generics market volume forecast: % of total pharma volume, 2023-28
Figure 61: Forces driving competition in the generics market in Australia, 2023
Figure 62: Drivers of buyer power in the generics market in Australia, 2023
Figure 63: Drivers of supplier power in the generics market in Australia, 2023
Figure 64: Factors influencing the likelihood of new entrants in the generics market in Australia, 2023
Figure 65: Factors influencing the threat of substitutes in the generics market in Australia, 2023
Figure 66: Drivers of degree of rivalry in the generics market in Australia, 2023
Figure 67: Brazil generics market value: $ million, 2018-23
Figure 68: Brazil generics market volume: % of total pharma volume, 2018-23
Figure 69: Brazil generics market geography segmentation: % share, by value, 2023
Figure 70: Brazil generics market value forecast: $ million, 2023-28
Figure 71: Brazil generics market volume forecast: % of total pharma volume, 2023-28
Figure 72: Forces driving competition in the generics market in Brazil, 2023
Figure 73: Drivers of buyer power in the generics market in Brazil, 2023
Figure 74: Drivers of supplier power in the generics market in Brazil, 2023
Figure 75: Factors influencing the likelihood of new entrants in the generics market in Brazil, 2023
Figure 76: Factors influencing the threat of substitutes in the generics market in Brazil, 2023
Figure 77: Drivers of degree of rivalry in the generics market in Brazil, 2023
Figure 78: Canada generics market value: $ million, 2018-23
Figure 79: Canada generics market volume: % of total pharma volume, 2018-23
Figure 80: Canada generics market geography segmentation: % share, by value, 2023
Figure 81: Canada generics market value forecast: $ million, 2023-28
Figure 82: Canada generics market volume forecast: % of total pharma volume, 2023-28
Figure 83: Forces driving competition in the generics market in Canada, 2023
Figure 84: Drivers of buyer power in the generics market in Canada, 2023
Figure 85: Drivers of supplier power in the generics market in Canada, 2023
Figure 86: Factors influencing the likelihood of new entrants in the generics market in Canada, 2023
Figure 87: Factors influencing the threat of substitutes in the generics market in Canada, 2023
Figure 88: Drivers of degree of rivalry in the generics market in Canada, 2023
Figure 89: China generics market value: $ million, 2018-23
Figure 90: China generics market volume: % of total pharma volume, 2018-23
Figure 91: China generics market geography segmentation: % share, by value, 2023
Figure 92: China generics market value forecast: $ million, 2023-28
Figure 93: China generics market volume forecast: % of total pharma volume, 2023-28
Abbott Laboratories SA
Abdi Ibrahim Ilac Sanayi ve Ticaret AS
Ache Laboratorios Farmaceuticos SA
Adcock Ingram Holdings Ltd
Apotex Inc
Aspen Pharmacare Holdings Ltd
AstraZeneca Plc
Aurobindo Pharma Ltd
Bayer AG
Beacons Pharmaceuticals Pte Ltd
Biocad
Bluefish Pharmaceuticals AB
Cipla Ltd
CSPC Pharmaceutical Group Ltd
Daiichi Sankyo Co Ltd
Deva Holding AS
DOC Generici SRL
Dong Wha Pharma Co Ltd
Dongkook Pharmaceutical Co Ltd
Dr. Reddy's Laboratories Ltd
EMS SA
Esteve Pharmaceuticals SA
Eurofarma Laboratorios SA
Friulchem SpA
Hanmi Pharmaceuticals Co Ltd
Hansoh Pharmaceutical Group Co Ltd
Hikma Pharmaceuticals Plc
JW Holdings Corp
Laboratorios Silanes SA de CV
Les Laboratoires Servier SAS
Lupin Ltd
Navamedic ASA
Novartis AG
Novartis International AG
Pfizer Inc
Pharmstandard
PT Indofarma Tbk
PT Kalbe Farma Tbk
PT Sanbe Farma
PT Soho Global Health Tbk
Recordati SpA
R-Pharm
Sandoz Canada Inc
Sandoz Group AG
Sandoz Inc
Sanofi
Sawai Group Holdings Co Ltd
Sino Biopharmaceutical Ltd
Stada Arzneimittel AG
Sun Pharmaceutical Industries Ltd
Teva Canada Ltd
Teva Pharmaceutical Industries Ltd
Toho Holdings Co Ltd
Towa Pharmaceutical Co Ltd
Viatris Inc
Ìý
Ìý
*If Applicable.